首页 > 市场调查报告书 > 製药

非专利药生技仿製药

市场调查报告书

商品编码

1741193

Humira生物相似药市场：依产品类型、适应症、通路、病患年龄及地区划分

Humira Biosimilar Market, By Product Type, By Indication, By Distribution Channel, By Patient Age, By Geography

出版日期: 2025年03月26日 | 出版商:

Coherent Market Insights | 英文 155 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2025 年， Humira生物相似药市场规模估计为 15.405 亿美元，预计到 2032 年将达到 77.24 亿美元，2025 年至 2032 年的复合年增长率为 25.9%。

报告范围		报告详细信息
基准年	2024	2025年的市场规模	15.405亿美元
效能数据	2020-2024	预测期	2025-2032
预测期间：2025年至2032年的复合年增长率	25.90%	2032年价值预测	77.24亿美元

Humira）是生技药品用于治疗干癣和类风湿性关节炎等自体免疫疾病的生物製剂，是世界上最受欢迎的生技药品。在某些地区，Humira的专利保护到期后，生物相似药在安全性、有效性和品质方面与生技药品高度相似。这些生物相似药可以促进竞争并降低价格。生物相似药可以透过提供更经济的治疗选择来帮助降低成本并改善患者获得基本药物的途径。生物相似药已被证明与原厂生技药品一样有效和安全，使其成为干癣和类风湿性关节炎等疾病患者的可行选择。此外，生物相似药的可用性刺激了製药业的创新，鼓励製造商在不影响品质的情况下开发更实惠的治疗方案。这种市场竞争可以降低价格并提高患者的可近性，最终改善医疗保健结果。此外，生物相似药的引入还可以增加患者的选择和自主权，使患者能够根据自己的特定需求选择最具成本效益的治疗方法。

市场动态

专利到期、成本降低、自体免疫疾病盛行率增加以及有利的法规环境是预计在预测期内推动全球Humira生物相似药市场成长的关键因素。

例如，北美已有多个修美乐（Humira）生物相似药核准和许可，引领生物相似药的推广市场。该地区拥有支持生物相似药推广的法律体制和政策，这将增强市场竞争并带来潜在的成本节约。

然而，复杂的监管流程、智慧财产权和专利诉讼以及医生和患者的意识预计将在预测期内阻碍全球脑血管造影市场的成长。

研究的主要特点

本报告对全球Humira生物相似药市场进行了详细分析，并以 2024 年为基准年，展示了预测期 2025-2032 的市场规模和复合年增长率。
它还强调了各个领域的潜在商机，并说明了该市场的有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
该报告根据公司亮点、产品系列、关键亮点、财务表现和策略等参数，概述了全球Humira生物相似药市场的主要企业。
本报告的见解将使负责人和企业经营团队能够就未来的产品发布、高端市场策略、市场扩张和行销策略做出明智的决策。
全球Humira生物相似药市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
相关人员将透过全球Humira生物相似药市场分析中使用的各种策略矩阵更轻鬆地做出决策。

介绍
北美洲
- 美国
- 加拿大
欧洲
- 英国
- 德国
- 义大利
- 法国
- 西班牙
- 俄罗斯
- 其他欧洲国家
亚太地区
- 中国
- 印度
- 日本
- 东南亚国协
- 澳洲
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
中东
- 海湾合作委员会国家
- 以色列
- 其他中东地区
非洲
- 北非
- 中部非洲
- 南非

第十章竞争格局

公司简介
- Amgen Inc.
- Samsung Bioepis Co.
- Sandoz International GmbH（Novartis AG）
- Mylan NV
- Boehringer Ingelheim International GmbH
- Pfizer Inc.
- Fresenius Kabi AG
- Coherus BioSciences
- Biogen Inc
- AbbVie Inc
- Celltrion Inc.
- Rani Therapeutics Holdings, Inc.
- Teva Pharmaceutical Industries Ltd
- Merck & Co
- Viatris Inc.
- Alvotech
- Analysts'Views

第 11 章章节

参考
调查方法
关于出版商

简介目录

Product Code: CMI5925

Humira Biosimilar Market is estimated to be valued at USD 1,540.5 Mn in 2025 and is expected to reach USD 7,724.0 Mn by 2032, growing at a compound annual growth rate (CAGR) of 25.9% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 1,540.5 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	25.90%	2032 Value Projection:	USD 7,724.0 Mn

Humira is a biologic medication used to treat autoimmune conditions like psoriasis and rheumatoid arthritis and is the most popular biologic medication in the world. Following the expiration of patent protection for humira in some regions, biosimilars are highly similar copies of biologic medications in terms of safety, efficacy, and quality. These biosimilars encourage competition and may result in price reductions. They help lower costs and improve patient access to essential pharmaceuticals by offering more economical treatment options. Biosimilars have been proven to be just as effective and safe as the original biologic medications, making them a viable alternative for patients with conditions like psoriasis and rheumatoid arthritis. Additionally, the availability of biosimilars promotes innovation in the pharmaceutical industry, as it encourages manufacturers to develop more affordable treatment options without compromising quality. This competition in the market can drive down prices and increase accessibility for patients, ultimately leading to improved healthcare outcomes. Furthermore, the introduction of biosimilars can also enhance patient choice and autonomy, allowing them to select the most suitable and cost-effective treatment for their specific needs.

Market Dynamics

Patent expiration, cost savings, increasing prevalence of autoimmune diseases, favorable regulatory environment is major factors expected to drive growth of the global humira biosimilar market during the forecast period.

For instance, the market for multiple humira biosimilars has been approved and introduced in North America, which has led the way in the adoption of biosimilars. Due to the region's existing legal framework and policies supporting biosimilar adoption, there will likely be more market competition and potential cost reductions.

However, complex regulatory processes, intellectual property and patent litigation, and physician and patient awareness are expected to hamper the growth of the global cerebral angiography market over the forecast period.

Key features of the study:

This report provides in-depth analysis of the global humira biosimilar market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global humira biosimilar market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Amgen Inc., Samsung Bioepis Co., Ltd., Sandoz International GmbH (Novartis AG), Mylan N.V., Boehringer Ingelheim International GmbH, Pfizer Inc., Fresenius Kabi AG, Coherus BioSciences, Inc., Biogen Inc., AbbVie Inc., Celltrion Inc., Rani Therapeutics Holdings, Inc., Teva Pharmaceutical Industries Ltd, Merck & Co., Inc., Viatris Inc., and Alvotech.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global humira biosimilar market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global humira biosimilar market

Humira Biosimilar Market Detailed Segmentation:

By Product Type:
- Biosimilar Humira (Adalimumab)
- Interchangeable Biosimilar Humira
By Indication:
- Rheumatoid Arthritis
- Psoriasis
- Crohn's Disease
- Ulcerative Colitis
- Ankylosing Spondylitis
- Juvenile Idiopathic Arthritis
- Other Autoimmune Conditions
By Patient Age:
- Adult Patients
- Pediatric Patients
- Geriatric Patients
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Company Profiles:
- Amgen
- Samsung Bioepis Co., Ltd.
- Sandoz International GmbH (Novartis AG)
- Mylan N.V.
- Boehringer Ingelheim International GmbH
- Pfizer Inc.
- Fresenius Kabi AG
- Coherus BioSciences, Inc.
- Biogen Inc.
- AbbVie Inc.
- Celltrion Inc.
- Rani Therapeutics Holdings, Inc.
- Teva Pharmaceutical Industries Ltd
- Merck & Co., Inc.
- Viatris Inc.
- Alvotech

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Patient Age
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Patent expiration
- Cost savings
- Increasing prevalence of autoimmune diseases
- Favorable regulatory environment
Market Restraints
Market Opportunity
Key Highlights
Regulatory Scenario
Recent Trends
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Mergers Acquisitions, and Collaborations

4. Global Humira Biosimilar Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Humira Biosimilar Market, By Product Type, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Biosimilar Humira (Adalimumab)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Interchangeable Biosimilar Humira
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

6. Global Humira Biosimilar Market, By Indication, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Rheumatoid Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Psoriasis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Crohn's disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Ulcerative Colitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Ankylosing Spondylitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Juvenile Idiopathic Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Other Autoimmune Conditions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

7. Global Humira Biosimilar Market, By Patient Age, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Adult Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Pediatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Geriatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

8. Global Humira Biosimilar Market, By Distribution Channel, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

9. Global Humira Biosimilar Market, By Region, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021 -2032
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/ Region, 2020-2032, (US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

10. Competitive Landscape

Company Profiles
- Amgen Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Samsung Bioepis Co.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Sandoz International GmbH (Novartis AG)
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Mylan N.V.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Boehringer Ingelheim International GmbH
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Fresenius Kabi AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Coherus BioSciences
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Biogen Inc
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- AbbVie Inc
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Celltrion Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Rani Therapeutics Holdings, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Teva Pharmaceutical Industries Ltd
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Merck & Co
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Viatris Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Alvotech
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Analysts' Views

11. Section

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

Humira生物相似药市场：依产品类型、适应症、通路、病患年龄及地区划分